Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06403436 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
A Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by TOLREMO therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT06403436 is a Phase 1 study of Cancer and Advanced Solid Tumor that is actively recruiting participants, run by TOLREMO therapeutics. The registered enrollment target is 50 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT06403436, a Phase 1 study of Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by TOLREMO therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG TT125-802
Study Locations (7)
Other
- NEXT Oncology Barcelona - Barcelona
- Vall d'Hebron Institute of Oncology - Barcelona
- NEXT Oncology Madrid - Madrid
- Ente Ospedaliero Cantonale - Bellinzona
- Centre Hospitalier Universitaire Vaudois - Lausanne
Tennessee
- Sarah Cannon Research Institute Oncology Partners - Nashville
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06403436
The ClinicalTrials.gov registry entry for NCT06403436 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is TOLREMO therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which TT125-802 is the first listed.
NCT06403436 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Other, Tennessee, Virginia.
Frequently Asked Questions
What is clinical trial NCT06403436 about?
NCT06403436 is a clinical study titled "A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors". The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
What is the current status of trial NCT06403436?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-11-07. Estimated completion is 2026-12.
What conditions does trial NCT06403436 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, NSCLC, Kras G12C, Squamous Cell Lung Cancer.
What interventions are being tested in trial NCT06403436?
The interventions under investigation include: TT125-802 (DRUG).
Who is sponsoring clinical trial NCT06403436?
This trial is sponsored by TOLREMO therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06403436 being conducted?
This trial has 7 study locations across Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.